(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.34%) $0.935
(0.55%) $11.01
(0.21%) $0.801
(0.00%) $92.17
4 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.47%
-2.41% $ 5.26
@ $8.24
Wydano: 14 vas. 2024 @ 22:41
Zwrot: -36.13%
Poprzedni sygnał: vas. 13 - 22:50
Poprzedni sygnał:
Zwrot: 3.45 %
Live Chart Being Loaded With Signals
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 1.22M |
Średni wolumen | 1.21M |
Kapitalizacja rynkowa | 400.28M |
EPS | $0 ( 2024-02-15 ) |
Następna data zysków | ( $-0.950 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.040 |
ATR14 | $0.00800 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Cline Christopher R. | Sell | 54 | Common Stock |
2024-01-31 | Dube Eric M | Buy | 135 000 | Common Stock |
2024-02-01 | Dube Eric M | Sell | 9 106 | Common Stock |
2024-01-31 | Dube Eric M | Buy | 360 000 | Employee stock option (right to buy) |
2024-02-01 | Dube Eric M | Sell | 10 016 | Common Stock |
INSIDER POWER |
---|
89.25 |
Last 100 transactions |
Buy: 2 015 500 | Sell: 106 721 |
Wolumen Korelacja
Travere Therapeutics, Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Travere Therapeutics, Korelacja - Waluta/Towar
Travere Therapeutics, Finanse
Annual | 2023 |
Przychody: | $145.24M |
Zysk brutto: | $88.86M (61.18 %) |
EPS: | $-1.500 |
FY | 2023 |
Przychody: | $145.24M |
Zysk brutto: | $88.86M (61.18 %) |
EPS: | $-1.500 |
FY | 2022 |
Przychody: | $212.02M |
Zysk brutto: | $204.43M (96.42 %) |
EPS: | $-4.37 |
FY | 2021 |
Przychody: | $227.49M |
Zysk brutto: | $220.71M (97.02 %) |
EPS: | $-3.79 |
Financial Reports:
No articles found.
Travere Therapeutics,
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej